2. Search Result
Search Result
Results for "

Dravet

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

3

Peptides

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111052
    AZD7325

    		GABA Receptor Cytochrome P450 Neurological Disease Inflammation/Immunology
    AZD7325 is a potent and orally active partial selective PAM of GABAAα2 and Aα3 receptor (Ki=0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the Aα1 and Aα5 receptor subtypes . AZD7325 is a moderate CYP1A2 and a potent CYP3A4 inducer in vitro . AZD7325 has the potential for the investigation of anxiety and dravet syndrome . PAM: positive allosteric modulator.
    AZD7325
  • HY-W090292
    Olivetolic acid

    		Drug Intermediate Neurological Disease
    Olivetolic acid is a biosynthetic precursor of cannabinol acid (CBGA). Olivetolic acid exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Olivetolic acid can be used for the study of convulsion .
    Olivetolic acid
  • HY-172318
    IAMA-6

    		NKCC Neurological Disease
    IAMA-6 is a selective NKCC1 inhibitor with neuroprotective effects. IAMA-6 can be used for the study of brain conditions, including drug-resistant epilepsy (e.g. temporal lobe epilepsy (TLE) and Dravet syndrome (DrS)), autism spectrum disorders (ASD) and Down syndrome (DoS) .
    IAMA-6
  • HY-148410A
    Zorevunersen sodium

    STK-001 sodium

    		 Sodium Channel Neurological Disease
    Zorevunersen sodium is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen sodium increases Scn1a mRNA transcripts and elevates the expression level of NaV1.1 protein. Zorevunersen sodium restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen sodium can be used for research on Dravet syndrome .
    Zorevunersen sodium
  • HY-101248
    GR-46611

    		5-HT Receptor Cancer
    GR-46611 is a 5-HT1D receptor agonist. GR-46611 can be used in the research of bladder hyperactivity, leukemia .
    GR-46611
  • HY-148410
    Zorevunersen

    STK-001

    		 Sodium Channel Neurological Disease
    Zorevunersen is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen increases Scn1a mRNA transcripts and elevates the expression level of NaV1.1 protein. Zorevunersen restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen can be used for research on Dravet syndrome .
    Zorevunersen
  • HY-126429
    Nav1.1 activator 1

    		Sodium Channel Neurological Disease
    Nav1.1 activator 1 (compound 4), a highly potent Nav1.1 activator with BBB penetration, increases decay time constant τ of Nav1.1 currents at 0.03 μM along with significant selectivity against Nav1.2, Nav1.5, and Nav1.6 .
    Nav1.1 activator 1
  • HY-P5183
    Hm1a

    		Sodium Channel Neurological Disease
    Hm1a is a venom peptide and a selective hNaV1.1 activator with an EC50 of 7.5 nM. Hm1a enhances hNaV1.1 and hNaV1.3 channel currents via delayed inactivation. Hm1a restores action potential firing in Dravet syndrome GABAergic inhibitory interneurons, reduces interictal epileptiform discharges and whole-brain hyperexcitability, lowers seizure frequency, and rescues premature death in Dravet syndrome mice. Hm1a can be used for the research of neurological disease, such as Dravet syndrome .
    Hm1a
  • HY-148410C
    Zorevunensen negative control

    STK-001 negative control

    		 Sodium Channel Neurological Disease
    Zorevunensen (STK-001) negative control is the negative control form of Zorevunensen (HY-148410). Zorevunensen is an antisense oligonucleotide that is intended to increase the level of productive SCN1A mRNA and consequently increase the expression of the sodium channel Nav1.1 protein. Zorevunersen is used for the study of Dravet syndrome .
    Zorevunensen negative control
  • HY-155238
    E2730

    		GABA Receptor Neurological Disease
    E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) .
    E2730
  • HY-P5784
    δ-Buthitoxin-Hj1a

    		Sodium Channel Neurological Disease
    δ-Buthitoxin-Hj1a, a scorpion-venom peptide, is a potent NaV1.1 agonist with an EC50 of 17nM. δ-Buthitoxin-Hj1a can be used for the Dravet syndrome (DS) research .
    δ-Buthitoxin-Hj1a
  • HY-P5783
    δ-Buthitoxin-Hj2a

    		Sodium Channel Neurological Disease
    δ-Buthitoxin-Hj2a, a scorpion-venom peptide, is a potent NaV1.1 agonist with an EC50 of 32 nM. δ-Buthitoxin-Hj2a can be used for the Dravet syndrome (DS) research .
    δ-Buthitoxin-Hj2a
  • HY-111052R
    AZD7325 (Standard)

    		GABA Receptor Cytochrome P450 Neurological Disease Inflammation/Immunology
    AZD7325 (Standard) is the analytical standard of AZD7325. This product is intended for research and analytical applications. AZD7325 is a potent and orally active partial selective PAM of GABAAα2 and Aα3 receptor (Ki=0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the Aα1 and Aα5 receptor subtypes . AZD7325 is a moderate CYP1A2 and a potent CYP3A4 inducer in vitro . AZD7325 has the potential for the investigation of anxiety and dravet syndrome . PAM: positive allosteric modulator.
    AZD7325 (Standard)
  • HY-181575
    TPH2 agonist-1

    		Tryptophan Hydroxylase Neurological Disease
    TPH2 agonist-1 (compound 20e) is an orally active, blood-brain barrier permeable, 1,3,4-oxadiazol-2 (3H)-one-derived TPH2 agonist. TPH2 agonist-1 upregulates TPH2 expression, elevates 5-HT and GABA levels, and exhibits antiepileptic activity in SCN1A-deficient models. TPH2 agonist-1 stabilizes the electrophysiological activity of neuronal networks and inhibits abnormal spike and burst activities. TPH2 agonist-1 shows no significant hERG inhibition or cytotoxicity, and it can be used in studies related to severe myoclonic epilepsy of infancy (Dravet syndrome) .
    TPH2 agonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: